Monopar’s ALXN1840 Secures Rare Pediatric Disease Designation, Potential PRV
MNPR•The FDA granted Rare Pediatric Disease designation to ALXN1840, Monopar’s late-stage Wilson disease candidate, potentially unlocking a pediatric Priority Review Voucher upon NDA approval. Phase 3 data across 266 patients and 645 patient-years showed rapid, sustained copper mobilization versus standard of care over 48 weeks.
1. FDA Grants Rare Pediatric Disease Designation
The FDA has granted Rare Pediatric Disease designation to ALXN1840 for the treatment of Wilson disease, qualifying Monopar to receive a pediatric Priority Review Voucher upon NDA approval. RPD status applies to serious conditions primarily affecting patients under 18 and can shorten FDA review by several months.
2. Phase 3 Trial Demonstrates Efficacy
In the pivotal Phase 3 study, ALXN1840 achieved rapid and sustained copper mobilization over 48 weeks in 266 patients across 645 patient-years, significantly outperforming standard of care. The therapy also showed a favorable safety and tolerability profile in both previously treated and treatment-naïve cohorts.
3. Outlook and Strategic Implications
Monopar can leverage the potential Priority Review Voucher for accelerated review of future marketing applications or monetization through sale. The RPD designation enhances ALXN1840’s regulatory profile and bolsters the company’s position in the rare disease market.
